Abstract: Accurate and rapid differentiation of the outbreak strain ribotype 027 from other possible Clostridium difficile (C. difficile) strains, using stool samples, facilitates decision making for treatment options. Cell wall protein V (CwpV) contains a cell wall binding domain conserved among C. difficile strains and a variable domain which is antigenically different among C. difficile strains. In embodiments, antibodies against the 027-specific region in CwpV are used in diagnostic tests to detect ribotype 027 in culture or fecal samples.
Type:
Grant
Filed:
May 8, 2013
Date of Patent:
September 15, 2015
Assignee:
TECHLAB, INC.
Inventors:
Manli Y. Davis, Krista A. Williams, Jocelyn N. Browning, David M. Lyerly
Abstract: Provided herein are compositions designed to reduce or prevent bacterial infections (for example pneuomococcal infections), nasal carriage, nasal colonization, and central nervous system invasion. Provided herein is a composition comprising a pneumococcal neuraminidase, phosphocholine, pneumococcal teichoic acid, pneumococcal lipoteichoic acid, or an antigenic portion of either neuraminidase, phosphocholine, pneumococcal teichoic acid, pneumococcal lipoteichoic acid. Optionally, the composition can comprise any combination of a pneumococcal neuraminidase, a phosphocholine, a pneumococcal teichoic acid, a pneumococcal lipoteichoic acid or an antigenic portion of any one of these. Optionally the agents are detoxified. Further provided are methods of making and using the compositions disclosed herein. Specifically provided are methods of generating antibodies in a subject comprising administering to the subject an agent or composition taught herein.
Type:
Grant
Filed:
November 10, 2004
Date of Patent:
September 15, 2015
Assignee:
The UAB Research Foundation
Inventors:
Frederik W. Van Ginkel, David E. Briles, James M. Watt
Abstract: The present invention provides methods for treating a substance addiction-related behavior in a patient with a substance addiction, comprising the step of locally administering a therapeutically effective amount of a botulinum neurotoxin to a location on the patient's body or in the vicinity of the area which comes into contact with a smoking tool or addictive substance, thereby altering, reducing or eliminating sensations associated with behaviors associated with substance addiction. Botulinum neurotoxin may be administered to a dermal, subdermal, mucosal or submucosal location or to a muscle area or in the vicinity of the location to which a smoking tool or addictive substance contacts.
Abstract: A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens is described. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum, the merozoite surface protein 1 (MSP-1) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen1 (AMA1) of P. falciparum, in its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently.
Type:
Grant
Filed:
May 3, 2010
Date of Patent:
September 1, 2015
Assignee:
CADILA HEALTHCARE LIMITED
Inventors:
Reinhard Glueck, Agata Fazio, Viviana Giannino, Martin A Billeter
Abstract: The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine.
Abstract: The present invention relates to a gene expression and eradication system for Helicobacter pylori (H. pylori). In particular, the present invention relates to a genetic construct comprising, in the 5?-3? direction: (a) a promoter sequence and (b) a DNA sequence of interest, wherein the promoter sequence comprises a polynucleotide sequence capable of regulating expression of the DNA sequence of interest in Helicobacter pylori and wherein said promoter sequence is modified to comprise a tetracycline (tet) operator sequence.
Type:
Grant
Filed:
March 9, 2012
Date of Patent:
August 25, 2015
Assignee:
Ondek Pty Ltd
Inventors:
Mohammed Benghezal, Aleksandra Weronika Debowski, Miriam Sehnal, Yakhya Dieye, Se-Hoon Park, Barry Marshall
Abstract: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.
Type:
Grant
Filed:
April 22, 2013
Date of Patent:
August 25, 2015
Assignee:
Syntaxin Limited
Inventors:
Andreas Rummel, Tanja Weil, Aleksandrs Gutcaits
Abstract: Disclosed is a method and associated device for the rapid identification of viable bacterial contaminants in food products. The method detects viable microbes by using a combined ATP-bioluminescence immunoassay. Escherichia coli O157:H7 and Salmonella enterica serovar Typhimurium were selected as target organisms in various matrices including ground beef homogenate, apple juice, milk, and phosphate-buffered saline. Specific antibodies were immobilized on the surface of well plates in which the sample matrices were incubated. The plates were washed, and the wells were incubated with BacTiter-Glo reagent in Mueller-Hinton II broth. Bioluminescent output was measured with a luminometer and signal-to-noise ratios were calculated. The LOD was not affected by the presence of non-target cells. A strong linear correlation was observed between the number of cells and luminescent output over 4 orders of magnitude.
Abstract: A thermo-reversible thermoplastic pharmaceutical composition, comprising a botulinum toxin and a biocompatible poloxamer which provides thermoreversibility to the composition and additionally stabilizes the botulinum toxin, is described. The pharmaceutical composition can be administered to a patient as a liquid, and gels after administration into a sustained release drug delivery system from which the biologically active botulinum toxin is released over a multi-day period thereby localizing the drug as a depot and controlling release to enhance the therapeutic effect per dose.
Abstract: The present invention provides a method of increasing extracellular secretion of secretory proteins by co-expressing the secretory proteins with a mature cutinase. Cutinase can improve the permeability of E. coli cell membrane without destroying the membrane, and thus facilitate cross-membrane transfer of the secretory proteins co-expressed in E. coli. Increased extracellular secretion of target proteins can shorten cell culture time, reduce the formation of inclusion bodies and increase production of target proteins.
Abstract: The present invention relates to means and methods for determining neurotoxin activity. Specifically, it relates to a polypeptide having caspase activity comprising a large subunit and a small subunit wherein the caspase further comprises a neurotoxin cleavage site which upon cleavage activates the caspase activity. Also encompassed are polynucleotides encoding the polypeptides as well as vectors or host cells comprising the polynucleotides. The present invention further relates to a method for determining neurotoxin activity in a sample based on the polypeptide of the invention as well as the use of the polypeptide for determining neurotoxin activity in a sample, in general.
Abstract: The present invention relates to methods for treating diseases and disorders by administering a composition containing the neurotoxic component of a Clostridium botulinum toxin complex, wherein the composition is devoid of any other protein of the Clostridium botulinum toxin complex and wherein the composition is administered at short intervals and/or in high doses.
Abstract: The present invention relates to the use of a peptide of P0 ribosomal protein in the manufacture of a vaccine composition to control of ectoparasite infestations and therefore the transmission of their associated pathogens. This peptide is located between 267 and 301 amino acids of the P0 protein, and can be obtained by recombinant means or by chemical synthesis. This peptide can be fused to a carrier protein or peptide, or an immuno-carrier and be included in an oily formulation. The formulations comprising the peptide vaccine confer protection against ticks and ectoparasites known as “sea lice” without generating autoimmunity in the host organism. Among these ticks may be mentioned species as Rhipicephalus microplus, Rhipicephalus sanguineus and Ixodes scapularis, and between sea lice are those of the Caligus and Lepeophtheirus genera.
Type:
Grant
Filed:
September 26, 2011
Date of Patent:
July 21, 2015
Assignee:
Centro de Ingeniería Genética y Biotecnología
Inventors:
Alina Rodriguez Mallon, Erlinda Fernández Díaz, Mario Pablo Estrada Garcia, Yamila Carpio González
Abstract: Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, oxidized cardiolipins, which may be conjugated with a variety of attachment molecules, such as BSA, KLH, biotin, synthetic protein MAPS, IgY, streptavidin, or avidin, are described. Such oxidized cardiolipin, alone or complexed with one or more attachment molecules, are useful to detect anti-lipoidal antibodies (such as IgG and IgM antibodies) in subjects, for example, when used in ELISA plates. ELISA plates are described that permit the detection of anti-lipoidal antibodies and that permit the co-detection of nontreponemal and treponemal antibodies in biological samples.
Type:
Grant
Filed:
July 11, 2014
Date of Patent:
July 14, 2015
Assignees:
The United States of America as represented by the Secretary of the Department of Health and Human Services, Arlington Scientific Inc.
Inventors:
Arnold R. Castro, Himanshu Champaklal Mody
Abstract: The polynucleotide encoding the antigen Wb123 from the filarial nematode Wuchereria bancrofti, the major causative organism of lymphatic filariasis is provided, along with the polypeptide encoded by the polynucleotide. Methods for making the WM23 antigen, recombinant vectors encoding the Wb123 polynucleotide, and methods of detection of the Wb123 antigen through luciferase immunoprecipitation, ELISA and other detection systems are also provided.
Type:
Grant
Filed:
October 31, 2011
Date of Patent:
June 30, 2015
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Thomas B. Nutman, Doran Fink, Joseph Kubofcik, Peter D. Burbelo
Abstract: The medicament for the prevention or the relief of poisoning by large clostridial cytotoxins (LCTs), in particular Clostridium difficile toxins A and B (TcdA and TcdB), is characterized by containing as active ingredient at least one effector, namely an inhibitor or activator of the autocatalytic protease activity of LCTs (large clostridial cytotoxins).
Type:
Grant
Filed:
May 30, 2012
Date of Patent:
June 30, 2015
Assignee:
JOHANNES GUTENBERG-UNIVERSITAET MAINZ
Inventors:
Christoph Von Eichelstreiber, Jessica Reineke, Stefan Tenzer, Hansjoerg Schild, Maja Rupnik
Abstract: The invention provides a method for releasing capsular polysaccharide from S. aureus type 5 or type 8 cells, comprising the step of treating the cells with acid. The invention further provides a process for purifying capsular polysaccharide from S. aureus type 5 or type 8 cells comprising this method. Other processing steps may be included in the process, such as enzymatic treatment, e.g. to remove nucleic acid, protein and/or peptidoglycan contaminants; diafiltration, e.g. to remove low molecular weight contaminants; anion exchange chromatography, e.g. to remove residual protein; and concentration.
Type:
Grant
Filed:
November 1, 2010
Date of Patent:
June 23, 2015
Assignee:
GlaxoSmithKline Biologicals SA
Inventors:
Paolo Costantino, Maria Rosaria Romano, Francesco Berti
Abstract: Cosmetic compositions include a Clostridial neurotoxin component and a microsphere component. In certain compositions, the composition includes a botulinum toxin and a plurality of swellable microspheres. The compositions are administered to individuals, by injection and the like, to treat a cosmetic defect of deficiency.
Abstract: To improve the stability of vaccines comprising aluminum salt(s), the invention uses the amino acid histidine. This can improve pH stability and adjuvant adsorption and can reduce antigen hydrolysis. Histidine is preferably present during adsorption to the aluminum salt(s). The antigen in the vaccine may be a protein or a saccharide and is preferably from N. meningitidis.